Abstract:Background Current approaches fail to separate patients at high versus low risk for ventricular arrhythmias owing to overreliance on a snapshot left ventricular ejection fraction measure. We used statistical machine learning to identify important cardiac imaging and time‐varying risk predictors. Methods and Results Three hundred eighty‐two cardiomyopathy patients (left ventricular ejection fraction ≤35%) underwent cardiac magnetic resonance before primary prevention implantable cardioverter defibrillator insertion. The primary end point was appropriate implantable cardioverter defibrillator discharge or sudden death. Patient characteristics; serum biomarkers of inflammation, neurohormonal status, and injury; and cardiac magnetic resonance‐measured left ventricle and left atrial indices and myocardial scar burden were assessed at baseline. Time‐varying covariates comprised interval heart failure hospitalizations and left ventricular ejection fractions. A random forest statistical method for survival, longitudinal, and multivariable outcomes incorporating baseline and time‐varying variables was compared with (1) Seattle Heart Failure model scores and (2) random forest survival and Cox regression models incorporating baseline characteristics with and without imaging variables. Age averaged 57±13 years with 28% women, 66% white, 51% ischemic, and follow‐up time of 5.9±2.3 years. The primary end point (n=75) occurred at 3.3±2.4 years. Random forest statistical method for survival, longitudinal, and multivariable outcomes with baseline and time‐varying predictors had the highest area under the receiver operating curve, median 0.88 (95% CI, 0.75‐0.96). Top predictors comprised heart failure hospitalization, left ventricle scar, left ventricle and left atrial volumes, left atrial function, and interleukin‐6 level; heart failure accounted for 67% of the variation explained by the prediction, imaging 27%, and interleukin‐6 2%. Serial left ventricular ejection fraction was not a significant predictor. Conclusions Hospitalization for heart failure and baseline cardiac metrics substantially improve ventricular arrhythmic risk prediction. Nonstandard Abbreviations and Acronyms LGE late gadolinium enhancement RF‐SLAM random forest survival, longitudinal and multivariate outcomes SCD sudden cardiac death SI signal intensity Clinical Perspective What Is New? In primary prevention implanted cardioverter defibrillator (ICD) recipients, an interim hospitalization for heart failure identified a group at high risk for subsequent ventricular arrhythmia defined as an appropriate ICD shock. Among ICD recipients without heart failure hospitalizations, baseline cardiac magnetic resonance imaging metrics (specifically, left ventricle heterogeneous gray and total scar, left ventricle and left atrial volumes, and left atrial total emptying fraction) as well as serum interleukin‐6 levels were the strongest predictors of subsequent appropriate ICD shock; serial left ventricle ejection fraction did not provide additional prognostic value for the arrhythmic outcome. Machine learning statistical methods may improve risk score development by accounting for complex and dynamic interactions among risk variables and temporally varying risk. What Are the Clinical Implications? The combination of clinical heart failure course, baseline cardiac magnetic resonance imaging metrics, and levels of the inflammatory biomarker interleukin‐6 can most accurately stratify subsequent high versus low ventricular arrhythmic risk and may be useful for decision‐making as primary prevention ICD recipients approach elective generator change. Identifying patients most at risk for ventricular arrhythmias and sudden cardiac death (SCD) remains a clinical challenge. 1 Current guidelines directing the use of primary prevention implanted cardioverter defibrillator (ICDs) rely on a reduced left ventricular ejection fraction (LVEF), which has low predictive efficiency. 1 Estimated annualized rates of appropriat -Abstract Truncated-

Transatlantic differences in the use of implantable cardioverter defibrillators in arrhythmogenic right ventricular cardiomyopathy

Implantable cardioverter defibrillator use in arrhythmogenic right ventricular cardiomyopathy in North America and Europe

Subcutaneous and Transvenous Defibrillators in Arrhythmogenic Right Ventricular Cardiomyopathy

Implantable Cardioverter Defibrillator Tachycardia Therapies: Past, Present and Future Directions

Management of arrhythmogenic right ventricular cardiomyopathy

Risk stratification for ventricular tachyarrhythmia in patients with nonischemic cardiomyopathy

Evolution of risk stratification and sudden death prevention in hypertrophic cardiomyopathy: Twenty years with the implantable cardioverter-defibrillator

Ventriculo-arterial (VA) coupling and fQRS as new selection criteria for primary prevention ICD placement

Decision-making regarding subcutaneous implantable cardioverter defibrillator as primary prevention in patients with low ejection fraction

Competing risks of monomorphic vs. non-monomorphic ventricular arrhythmias in primary prevention implantable cardioverter-defibrillator recipients: Global Electrical Heterogeneity and Clinical Outcomes (GEHCO) study

Trans-Atlantic Differences in Approach to Sudden Death Prevention in Patients With Hypertrophic Cardiomyopathy

Baseline and Dynamic Risk Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy.

Are we implanting too many primary prevention implantable cardioverter defibrillators?

Arrhythmic risk stratification in ischemic, non-ischemic and hypertrophic cardiomyopathy: A two-step multifactorial, electrophysiology study inclusive approach

Risk of Appropriate Implantable Cardioverter-Defibrillator Therapies and Sudden Cardiac Death in Patients With Heart Failure With Improved Left Ventricular Ejection Fraction

A new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy

Subcutaneous ICD Implantation and Catheter Ablation: A Step-Planned Approach for Ventricular Tachycardia Management in ARVC

Arrhythmogenic right ventricular cardiomyopathies (ARVC): Diagnostic challenges from imaging to genetics

Advances in Research of Arrhythmogenic Right Ventricular Cardiomyopathy

Management of ventricular tachycardia in patients with ischaemic cardiomyopathy: contemporary armamentarium

Sudden Cardiac Death in Ischaemic Cardiomyopathy and the Primary Prevention ICD: Time for a More a Personalised Approach?